Open Access<p>Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism</p>
Author(s) -
Satoko Kawarasaki,
Honami Sawazaki,
Hiroaki Iijima,
Su-Ping Ng,
Jungin Kwon,
Shinsuke Mohri,
Mari Iwase,
HueiFen Jheng,
Haruya Takahashi,
Wataru Nomura,
Kazuo Inoue,
Teruo Kawada,
Tsuyoshi Goto
Publication year - 2020
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s269916
Subject(s) - canagliflozin , endocrinology , oral administration , adipose tissue , medicine , dosing , weight gain , pharmacology , lipid metabolism , fatty acid synthesis , chemistry , beta oxidation , fatty acid , type 2 diabetes , diabetes mellitus , metabolism , body weight , biochemistry
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have various pleiotropic effects, including body weight reduction, and therefore have the potential to be used in various applications. However, such effects have not been fully investigated; thus, non-clinical studies using animal models are needed. In animal experiments, SGLT2 inhibitors are usually administered by oral or dietary methods. However, the detailed characteristics of these dosing methods, especially to induce their pleiotropic effects, have not been reported. Therefore, we compared the preventive effects of canagliflozin, an SGLT2 inhibitor, on body weight gain following oral gavage and dietary administration methods in a mouse model of diet-induced obesity.